Moneyta · stock research · no sign-up needed
EW
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q2 FY2026)
$1.7B
+23.2% y/y
Net income (Q2 FY2026)
$242M
as filed with the SEC
Institutions holding
1,342
+46 last quarter
Overview · Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. T…
Management team
- Mr. Daveen Chopra · Corporate Vice President of Transcatheter Mitral & Tricuspid TherapiesFind on LinkedIn
- Mr. Jean-Luc Lemercier · Corporate Vice President of Japan, Asia Pacific & Greater ChinaFind on LinkedIn
- Mr. Larry L. Wood · Corporate VP and Group President of TAVR & Surgical Structural HeartFind on LinkedIn
- Mr. Donald E. Bobo Jr. · Corporate Vice President of Strategy & Corporate DevelopmentFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on EW
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.